During the life cycle of an authorised medicinal product, a significant change may occur in the standard of care for the diagnosis, treatment or prevention of a disease, leading to the need to re-open discussions on the established benefit-risk balance of the medicinal product. The European Court of Justice has ruled that a modified consensus within the medical community regarding the appropriate assessment criteria of the therapeutic efficacy of a medicinal product may constitute concrete and objective factors capable of acting as a basis for the finding of a negative benefit-risk assessment of that product [Case C-221/10P Artegodan v Commission, not yet published, paragraphs 100-103.]. It may therefore be necessary to provide new evidence on the efficacy of the medicinal product to maintain a positive benefit-risk assessment. Likewise, if an improved understanding of the disease or the pharmacology of a medicinal product has brought into question the criteria used to establish the efficacy of the medicinal product at the time the marketing authorisation was granted, additional studies may be considered.
Recital 10, Commission Delegated Regulation (EU) No 357/2014 of 3 February 2014 supplementing Direct…
In forcesince 3 Feb 2014
Judgment of the Court (Third Chamber), 19 April 2012. Artegodan GmbH v European Commission.Decision
19 Apr 2012 · 62010CJ0221